177Lu-PSMA SPECT定量分析在第6周(第2剂)可预测接受177Lu-PSMA-I&T治疗患者的短无进展生存期
本研究纳入127例进展性转移性去势抵抗性前列腺癌男性患者,接受中位3剂177Lu-PSMA-I&T治疗,于第1周期(基线)和第2周期(第6周)行177Lu SPECT/CT定量分析。结果显示,第6周SPECT总肿瘤体积(TTV)任何程度的增加与显著更短的前列腺特异性抗原(PSA)无进展生存期(PFS)相关(HR 2.5,95%CI 1.5-4.2,P=0.0008),但与总生存期(OS)无关。
要点
- 第6周SPECT TTV任何增加与显著更短PSA PFS相关(HR 2.5,95%CI 1.5-4.2,P=0.0008)。
- SPECT TTV增加者中位PSA PFS为3.7个月,无增加者为6.7个月。
- PSA与SPECT TTV均升高者较两者均降低者PSA PFS更短(中位2.8 vs 9.0个月,P<0.0001)。
核心结论
- 定量177Lu SPECT/CT上PSMA SPECT TTV增加可预测短无进展生存期,未来可能作为影像应答生物标志物,用于识别何时停止或强化177Lu-PSMA治疗。
研究设计与样本
- 本研究纳入127例进展性转移性去势抵抗性前列腺癌男性患者,既往接受雄激素信号抑制治疗者占99%、化疗者占71%,接受中位3剂(四分位距2-5)8 GBq(四分位距8-8.5 GBq)的177Lu-PSMA-I&T治疗。
- 影像检查包括68Ga-PSMA-11 PET/CT(单部位SUVmax>15且所有>2 cm部位SUVmax>10)、诊断性CT及治疗后24小时从头顶至大腿中部的177Lu SPECT/CT,于第1周期(基线)和第2周期(第6周)进行定量分析。
主要发现
- 58%(74/127)患者PSA下降超过50%,中位PSA PFS为6.1个月(95%CI 5.5-6.7),OS为16.8个月(95%CI 13.5-20.1),分析时41%(52/127)已死亡。
- 基线和第6周均有可分析连续177Lu SPECT/CT影像者占76%(96/127),其中74%(71/96)第6周SPECT TTV较基线缩小(中位-193,四分位距-486至-41)。
- 第6周SPECT TTV任何增加与显著更短PSA PFS相关(HR 2.5,95%CI 1.5-4.2,P=0.0008),但与OS无关;SPECT TTV增加者中位PSA PFS为3.7个月(95%CI 2.8-6.8),无增加者为6.7个月(95%CI 5.8-10.6)。
- SPECT TTV增加超过20%亦与PSA PFS相关(HR 1.9,95%CI 1.2-3.0,P=0.008),但显著性低于SPECT TTV任何变化。
- PSA与SPECT TTV均升高者较SPECT TTV与PSA均降低者PSA PFS有显著差异(中位2.8 vs 9.0个月,P<0.0001)。
临床怎么用
- 作者认为,定量177Lu SPECT/CT上PSMA SPECT TTV增加可预测短无进展生存期,未来可能作为影像应答生物标志物,用于识别何时停止或强化177Lu-PSMA治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-PSMA is an effective treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and adjust treatment may be improved using predictive tools. This study aimed to evaluate change in 177Lu-PSMA SPECT quantitative parameters to monitor treatment response. Methods: One hundred twenty-seven men with progressive mCRPC previously treated with androgen-signaling inhibition (99%) and chemotherapy (71%) received a median of 3 (interquartile range [IQR], 2-5) 8-GBq (IQR, 8-8.5 GBq) doses of 177Lu-PSMA-I&T. Imaging included 68Ga-PSMA-11 PET/CT (SUVmax > 15 at a single site and > 10 at all sites > 2 cm), diagnostic CT, and 177Lu SPECT/CT from vertex to mid thigh (24 h after treatment). 177Lu SPECT/CT quantitative analysis was undertaken at cycles 1 (baseline) and 2 (week 6) of treatment. Clinical and biochemical results were assessed to evaluate prostate-specific antigen (PSA) progression-free survival (PFS) and overall survival (OS). Results: A PSA reduction of more than 50% was seen in 58% (74/127). The median PSA PFS was 6.1 mo (95% CI, 5.5-6.7), and OS was 16.8 mo (95% CI, 13.5-20.1). At the time of analysis, 41% (52/127) were deceased. At baseline and week 6, 76% (96/127) had analyzable serial 177Lu SPECT/CT imaging. SPECT total tumor volume (TTV) was reduced between baseline and week 6 in 74% (71/96; median, -193; IQR, -486 to -41). Any increase in SPECT TTV between baseline and week 6 was associated with significantly shorter PSA PFS (hazard ratio, 2.5; 95% CI, 1.5-4.2; P = 0.0008) but not OS. Median PSA PFS in those with an increase in SPECT TTV was 3.7 mo (95% CI, 2.8-6.8), compared with 6.7 mo (95% CI, 5.8-10.6) in those with no increase in SPECT TTV. An increase in SPECT TTV greater than 20% was also associated with PSA PFS (hazard ratio, 1.9; 95% CI, 1.2-3.0; P = 0.008) but less significantly than any change in SPECT TTV. There was a significant difference in PSA PFS between patients with both increased PSA and SPECT TTV and patients with reduced SPECT TTV and PSA (median, 2.8 vs. 9.0 mo; P < 0.0001). Conclusion: Increasing PSMA SPECT TTV on quantitative 177Lu SPECT/CT predicts short progression-free survival and may play a future role as an imaging response biomarker, identifying when to cease or intensify 177Lu-PSMA therapy.
引用
- John N, Pathmanandavel S, Crumbaker M, et al. 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy. J Nucl Med. 2022. PMID: 36215568. doi:10.2967/jnumed.122.264677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。